• Neurogene President, CFO, director Christine Mikail Cvijic reported sale of 9,600 common shares on May 6.
• Sales priced at USD 30.07 per share for 4,800 shares, USD 32.44 per share for 4,800 shares.
• Directly held stake fell to 93,640 shares following transactions.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Neurogene Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001543663-26-000013), on May 08, 2026, and is solely responsible for the information contained therein.